Douglas Reed, M.D.
General Partner, Hatteras Venture Partners, Chairman

Dr. Reed joined Hatteras Venture Partners as a General Partner in early 2007. Prior to Hatteras, Doug had 14 years of venture investing experience with two healthcare-focused funds, Vector Fund Management and SR One. He has been involved in venture investment transactions for over 30 healthcare and life science companies and currently serves as chairman of Viamet Pharmaceuticals Holdings, LLC, and as director of TetraLogic Pharmaceuticals and several private life sciences companies.

Andrew von Eschenbach, M.D.

Dr. von Eschenbach was the Commissioner of the US Food and Drug Administration from 2005 to 2009. Previously, Dr. von Eschenbach was Director of the US National Cancer Institute. Prior to his government service, he was an accomplished urologist and healthcare administrator. His medical career included several leadership roles at the University of Texas M.D. Anderson Cancer Center including Chair of the Department of Urology, founding Director of the Prostate Cancer Research Program, Director of the Genitourinary Cancer Center, Distinguished Chair in Urologic Oncology, and Executive Vice President and Chief Academic Officer.

James Rosen
General Partner, Intersouth Partners

Mr. Rosen joined the life science team at Intersouth in 2005. Previously, he spent 15 years in clinical, research and financial positions in the health care and biotechnology sectors. Jimmy worked on a Robert Wood Johnson Foundation sponsored program at the UNC Lineberger Comprehensive Cancer Center. He was also an equity research analyst at Brean Murray & Co. for three years, covering biopharmaceuticals, genomics, generics, drug delivery and medical device companies. He has worked in clinical research roles at Duke University Medical Center's Comprehensive Cancer Center and completed projects for the National Cancer Institute. At the beginning of his career in health care, Jimmy spent five years in Emergency Medical Services as a mountain search rescue and ambulance medic.

Jimmy holds a B.A. from Duke University, an M.B.A. from UNC-Chapel Hill's Kenan-Flagler Business School, and an M.S.P.H. from the UNC School of Public Health. He was a Carolina Venture Fellow at Kenan-Flagler, and recipient of the Frank Hawkins Kenan Award for Excellence. He currently serves on the Public Health Foundation Board for the UNC Gillings School of Global Public Health and is a director of Viamet Pharmaceuticals, Applied Genetics Technology Corporation and several private companies.

Robert Schotzinger, M.D., Ph.D.
President & CEO

Dr. Schotzinger brings over 20 years of research, development and management experience to Viamet, where he has raised significant equity capital and moved Viamet from a seed-stage company to a clinical-stage company. Prior to joining Viamet, Dr. Schotzinger was President and CEO of BioStratum Inc., a privately-held biotechnology company, where he was responsible for moving the company's lead drug candidate from phase 1 to phase 3. Dr. Schotzinger began his pharmaceutical career at Abbott Laboratories where he held positions of increasing responsibility, including Director of International Medical Affairs and Vice President of Drug Development. While at Abbott, he gained experience in preclinical and clinical drug development and was involved in the filing and approval of multiple NDAs, SNDAs, ANDAs and INDs.

Dr. Schotzinger received his B.S. in Pharmacy from the Ohio State University. He subsequently earned his Ph.D. degree in pharmacology and medical degree from Case Western Reserve University. He also completed a residency at the University of Virginia, which led to Board Certification in Internal Medicine.

Lauren Silverman, Ph.D.
Managing Director, Novartis Venture Fund

Dr. Silverman is a Managing Director of the Novartis Venture Fund in Cambridge, MA, USA. Prior to joining the Novartis Venture Fund, she was Global Head of Oncology Research Operations for Novartis. Previously, Lauren spent much of her career in business development and licensing functions, first at OSI Pharmaceuticals and later at Pfizer. Lauren was also a Director of Strategic Alliances and Head of Cell Biology where she led multiple research teams after having been a founding scientist of Cadus Corporation (formerly Cadus Pharmaceutical Corporation). Lauren was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and Princeton University and earned her Ph.D. in molecular biology from the University of Utah. Lauren serves on the Business Advisory Board of the Epilepsy Research Foundation's Epilepsy Therapy Project, and the Steering Committee of Brigham and Women’s Hospital. Lauren currently serves on the Boards of Directors of Viamet Pharmaceutical Holdings, LLC and several private life sciences companies.

S. Edward Torres
Managing Director, Lilly Ventures

Mr. Torres is a managing director of Lilly Ventures Fund I LLC and brings over 20 years of pharmaceutical and venture capital experience to the team. Ed currently sits on the boards of Viamet Pharmaceuticals Holdings, LLC, Receptos, several private life sciences companies and various non-profit institutions. Prior to his role in Lilly Ventures, Ed had a diverse set of experiences throughout the domestic and international pharmaceutical businesses of Eli Lilly including operational finance, planning, M&A, business development and global marketing roles. Ed received a B.A. from Creighton University and a M.B.A. from the University of Michigan Business School, where he was a Consortium Fellow.

Kristopher Wood
Chief Investment Officer, Lurie Holdings Inc.

Kristopher is the chief investment officer at Lurie Holdings Inc.. Prior to Lurie Holdings, he served as head of strategy and corporate development at World Color, a printing company. Previously, he was also an associate at MidOcean Partners, a private equity company. Kris also served as chief acquisitions officer for Glenayre Inc. and as managing director for mergers and acquisitions and venture capital at Vertis Holdings, Inc. Kris serves on the board of directors of several private companies. He received a B.S. from the Wharton School of the University of Pennsylvania.